Clinical Trial Update: Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a new formulation of insulin glargine with Lantus in patients with Type 2 diabetes not adequately controlled on non-insulin therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (new formulation) (insulin glargine)
• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED